Skip to content

8-KAccepted Nov 12, 7:48 AM ET

Sagimet Biosciences Inc.: reports Q3 2026 financial results

SGMTSagimet Biosciences Inc.

Accepted (ET)

7:48 AM

Nov 12, 2026

Filed

Nov 12, 2026

Documents

47

Size

13.4 MB

Summary

Sagimet Biosciences Inc.: reports Q3 2026 financial results

Updated

What happened

  • On Nov 12, 2026, Sagimet Biosciences Inc announced its financial results for the quarter ended Sep 30, 2026 and furnished a press release as Exhibit 99.1 to the Form 8-K.
  • On Nov 12, 2026, the company updated information reflected in a slide presentation, which is attached as Exhibit 99.2, and said representatives will use the updated presentation in various meetings with investors from time to time.

Key details

  • The Form 8-K was filed on Nov 12, 2026 and includes Item 2.02 and Item 7.01 disclosures.
  • The financial results cover the quarter ended Sep 30, 2026.
  • Press release furnished as Exhibit 99.1; updated investor presentation furnished as Exhibit 99.2.

Why it may matter

  • Item 2.02 (results of operations and financial condition) reports the company’s announced financial results for the specified quarter. Item 7.01 (Regulation FD disclosure) reports the updated investor presentation that the company will use in investor meetings. The filing does not show why the insider traded or why the company acted.

AI-written summary · check the filing